Mundigl, Olaf

Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models

Herter, S., Herting, F., Mundigl, O., Waldhauer, I., Weinzierl, T., Fauti, T., Muth, G., Ziegler-Landesberger, D., Van Puijenbroek, E., Lang, S., et al. (2013) · Molecular Cancer Therapeutics

Lymphoma Diagnosis and TreatmentMonoclonal and Polyclonal Antibodies Research

Cited by 366

Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics

Schoch, A., Kettenberger, H., Mundigl, O., Winter, G., Engert, J., Heinrich, J., & Emrich, T. (2015) · Proceedings of the National Academy of Sciences

Monoclonal and Polyclonal Antibodies ResearchProtein purification and stability

Cited by 202

Quantitative fluorescence imaging determines the absolute number of locked nucleic acid oligonucleotides needed for suppression of target gene expression

Buntz, A., Killian, T., Schmid, D., Seul, H., Brinkmann, U., Ravn, J., Lindholm, M., Knoetgen, H., Haucke, V., & Mundigl, O. (2019) · Nucleic Acids Research

RNA Interference and Gene DeliveryDNA and Nucleic Acid Chemistry

Cited by 52